In a clinical context, we found that the expression level of PRRX1 in tumor tissues from 48 lung cancer patients was positively correlated with poor prognosis and a reduced response to anti-PD-1 therapy (Fig. 4H–J). This evidence concerns the gene PDCD1 and neoplasm.